Mounjaro™ for Weight Loss

Posted: Jun 22 in Weight Loss Medication by

The FDA has approved a very exciting medication called Mounjaro™. Although approved for treatment of type 2 diabetes, a side effect of Mounjaro™ is weight loss. The same molecule, tirzapeptide, is being researched for weight loss as well.

Mounjaro™ is the newest in the class of GLP-1 analogues. GLP-1 (glucagon-like peptide 1) is a hormone that the body naturally makes in response to food intake. It signals the body that we are in a fed state (satiated), and lowers blood sugar. Human GLP-1 only lasts a few minutes, but Mounjaro lasts a whole week. In addition, it contains GIP (Gastric inhibitory peptide), another hormone with similar properties.

Similar to Wegovy™, Mounjaro is available as a once weekly injectable medication (self-administered). In the studies for type II diabetes, people lost an average of 25 pounds on the 15 mg weekly dose. Note that this was a side effect when used for diabetes treatment – in the first study for weight loss, people lost an average of 52 pounds (22.5%) on the 15 mg dose, with 63% of people losing more than 20% of their body weight (click here to read more).

The graph below shows the weight loss from the diabetes trail:

Side effects are mostly gastrointestinal – nausea, etc., and for most patients, gradually improve over time. For more information on side effects, contraindications, etc., click here.

Leave Comment